Sally Blount - Abbott Laboratories Independent Director
| ABTT34 Stock | BRL 56.88 0.66 1.17% |
Director
Ms. Sally E. Blount, Ph.D., serves as Independent Director of the Company. Ms. Blount has served as Dean of the J.L. Kellogg Graduate School of Management and the Michael L. Nemmers Professor of Management and Organizations at Northwestern University since July 2010. From 2004 to 2010, she served as the Vice Dean and Dean of the undergraduate college of New York University Leonard N. Stern School of Business. Ms. Blount joined the faculty of New York University Leonard N. Stern School of Business in 2001 and was the Abraham L. Gitlow Professor of Management and Organizations. Prior to joining NYU in 2001, Ms. Blount held academic posts at the University of Chicago Graduate School of Business from 1992 to 2001 since 2011.
| Age | 57 |
| Tenure | 13 years |
| Phone | 224 667 6100 |
| Web | https://www.abbott.com |
Abbott Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.0882 % which means that it generated a profit of $0.0882 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1928 %, meaning that it generated $0.1928 on every $100 dollars invested by stockholders. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 8 records | DIRECTOR Age | ||
| Clarence Otis | Verizon Communications | 63 | |
| Shellye Archambeau | Verizon Communications | 56 | |
| Melanie Healey | Verizon Communications | 57 | |
| Daniel Schulman | Verizon Communications | 61 | |
| Carlos Filho | G2D Investments | N/A | |
| Mark Bertolini | Verizon Communications | 62 | |
| Rodney Slater | Verizon Communications | 64 | |
| Gregory Weaver | Verizon Communications | 67 | |
Management Performance
| Return On Equity | 0.19 | |||
| Return On Asset | 0.0882 |
Abbott Laboratories Leadership Team
Elected by the shareholders, the Abbott Laboratories' board of directors comprises two types of representatives: Abbott Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abbott. The board's role is to monitor Abbott Laboratories' management team and ensure that shareholders' interests are well served. Abbott Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abbott Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Samuel Scott, Independent Director | ||
| Christopher Scoggins, Senior Vice President - Rapid Diagnostics | ||
| Jaime Contreras, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations | ||
| Mary Moreland, Executive Vice President of Human Resources | ||
| Roger Bird, Senior Vice President - U.S. Nutrition | ||
| Michael Dale, Senior Vice President - Structural Heart | ||
| Nancy McKinstry, Independent Director | ||
| Sammy Karam, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
| Phebe Novakovic, Independent Director | ||
| Andrew Lane, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
| Roxanne Austin, Independent Director | ||
| Sally Blount, Independent Director | ||
| Randel Woodgrift, Senior Vice President - CRM | ||
| Daniel Starks, Independent Director | ||
| Michelle Kumbier, Independent Director | ||
| Michael Pederson, Senior Vice President - Electrophysiology and Heart Failure | ||
| Lisa Earnhardt, Executive Vice President - Medical Devices | ||
| John Capek, Executive Vice President - Ventures | ||
| Alejandro Wellisch, Senior Vice President - Established Pharmaceuticals, Latin America | ||
| Robert Alpern, Independent Director | ||
| Miles White, Chairman, CEO and Chairman of Executive Committee | ||
| Robert Ford, President, Chief Executive Officer, Chief Operating Officer, Director | ||
| Glenn Tilton, Independent Director | ||
| Elaine Leavenworth, VP Officer | ||
| Darren McDew, Independent Director | ||
| Charles Brynelsen, Senior Vice President - Abbott Vascular | ||
| Edward Liddy, Independent Director | ||
| Hubert Allen, Executive Vice President, General Counsel, Secretary | ||
| John Stratton, Independent Director | ||
| Joseph Manning, Senior Vice President - Abbott Nutrition International | ||
| Scott Leinenweber, Licensing Relations | ||
| James Young, VP Officer | ||
| John Ginascol, Executive Vice President - Core Diagnostics | ||
| Jared Watkin, Senior Vice President - Diabetes Care | ||
| William Osborn, Lead Independent Director | ||
| Robert Funck, Chief Financial Officer, Executive Vice President - Finance | ||
| Daniel Salvadori, Senior Vice President - Established Pharmaceuticals, Latin America. | ||
| Andrea Wainer, Executive Vice President - Rapid and Molecular Diagnostics | ||
| Melissa Brotz, VP Marketing |
Abbott Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abbott Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.0882 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 1.07 T | |||
| Shares Outstanding | 20.92 B | |||
| Price To Earning | 40.47 X | |||
| Price To Book | 5.41 X | |||
| Price To Sales | 22.38 X | |||
| Revenue | 43.65 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Abbott Stock
When determining whether Abbott Laboratories is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Abbott Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Abbott Laboratories Stock. Highlighted below are key reports to facilitate an investment decision about Abbott Laboratories Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Abbott Stock refer to our How to Trade Abbott Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.